Background Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which cerebral glucose hypometabolism represents one of the earliest and most consistent pathological abnormalities, often preceding classical amyloid and tau pathology. Here, MAPT is linked to Alzheimer disease.